http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Kojima Tsukasa,Yamasaki Yuzo,Kamitani Takeshi,Yabuuchi Hidetake,Shirasaka Takashi,Shimomiya Yamato,Kondo Masatoshi,Hamasaki Hiroshi,Kato Toyoyuki,Nagao Michinobu,Honda Hiroshi 아시아심장혈관영상의학회 2019 Cardiovascular Imaging Asia Vol.3 No.1
Objective: The smallest diagnostically sufficient amount of contrast media (CM) should be used for coronary computed tomography angiography (CCTA) to minimize the risk of contrast- induced nephrotoxicity in elderly patients with coronary artery disease. The purpose of this study was to propose dynamic-CCTA using a low dose of CM and temporal maximum intensity projection (TMIP) and to investigate its image quality compared to standard-CCTA. Materials and Methods: Participants comprised 30 patients with coronary artery disease who underwent dynamic-CCTA and standard-CCTA using 320-row CT. Dynamic-CCTA was continuously performed at mid-diastole throughout 15–25 cardiac cycles after bolus injection of CM [103 mg iodine/kg body weight (mgI/kg)]. TMIP-CCTA was reconstructed from three-phase dynamic-CCTA data, including a phase with peak enhancement of the ascending aorta. Standard-CCTA was performed using a standard CM dose (259 mgI/kg). Image quality of both TMIP-CCTA and standard-CCTA was analyzed. Results: The amount of CM used in TMIP-CCTA and standard-CCTA was 16.2±2.6 mL and 40.1±7.3 mL, respectively. The mean effective radiation dose was not significantly different between the two methods. Mean coronary attenuation was significantly lower for TMIP-CCTA than standard-CCTA [346.9±82.8 Hounsfield units (HU) vs. 455.4±75.3 HU, p<0.05]. Image noise was significantly lower for TMIP-CCTA than standard-CCTA (20.0±3.2 HU vs. 28.1± 3.6 HU, p<0.05). There were no differences in signal-to-noise ratio and visual assessment scores between the two methods. Conclusion: TMIP-CCTA can be performed using more than 50% less CM with the same image quality as standard-CCTA.
Arata Sakai,Atsuhiro Masuda,Takaaki Eguchi,Keisuke Furumatsu,Takao Iemoto,Shiei Yoshida,Yoshihiro Okabe,Kodai Yamanaka,Ikuya Miki,Saori Kakuyama,Yosuke Yagi,Daisuke Shirasaka,Shinya Kohashi,Takashi Ko 대한소화기내시경학회 2024 Clinical Endoscopy Vol.57 No.3
Background/Aims: Endoscopic self-expandable metal stent (SEMS) placement is currently the standard technique for treating unresectable malignant distal biliary obstructions (MDBO). Therefore, covered SEMS with longer stent patency and fewer migrations are required. This study aimed to assess the clinical performance of a novel, fully covered SEMS for unresectable MDBO. Methods: This was a multicenter single-arm prospective study. The primary outcome was a non-obstruction rate at 6 months. The secondary outcomes were overall survival (OS), recurrent biliary obstruction (RBO), time to RBO (TRBO), technical and clinical success, and adverse events. Results: A total of 73 patients were enrolled in this study. The non-obstruction rate at 6 months was 61%. The median OS and TRBO were 233 and 216 days, respectively. The technical and clinical success rates were 100% and 97%, respectively. Furthermore, the rate of occurrence of RBO and adverse events was 49% and 21%, respectively. The length of bile duct stenosis (<2.2 cm) was the only significant risk factor for stent migration. Conclusions: The non-obstruction rate of a novel fully covered SEMS for MDBO is comparable to that reported earlier but shorter than expected. Short bile duct stenosis is a significant risk factor for stent migration.